Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 42

1.

Developmental study of fragile X syndrome using human embryonic stem cells derived from preimplantation genetically diagnosed embryos.

Eiges R, Urbach A, Malcov M, Frumkin T, Schwartz T, Amit A, Yaron Y, Eden A, Yanuka O, Benvenisty N, Ben-Yosef D.

Cell Stem Cell. 2007 Nov;1(5):568-77. doi: 10.1016/j.stem.2007.09.001.

2.

Repeat-induced epigenetic changes in intron 1 of the frataxin gene and its consequences in Friedreich ataxia.

Greene E, Mahishi L, Entezam A, Kumari D, Usdin K.

Nucleic Acids Res. 2007;35(10):3383-90. Epub 2007 May 3.

3.

Sirtuins in mammals: insights into their biological function.

Michan S, Sinclair D.

Biochem J. 2007 May 15;404(1):1-13. Review.

4.

Regional FMRP deficits and large repeat expansions into the full mutation range in a new Fragile X premutation mouse model.

Entezam A, Biacsi R, Orrison B, Saha T, Hoffman GE, Grabczyk E, Nussbaum RL, Usdin K.

Gene. 2007 Jun 15;395(1-2):125-34. Epub 2007 Mar 16.

5.

Functions of site-specific histone acetylation and deacetylation.

Shahbazian MD, Grunstein M.

Annu Rev Biochem. 2007;76:75-100. Review.

PMID:
17362198
6.

A homogeneous assay for analysis of FMR1 promoter methylation in patients with fragile X syndrome.

Dahl C, Grønskov K, Larsen LA, Guldberg P, Brøndum-Nielsen K.

Clin Chem. 2007 Apr;53(4):790-3. Epub 2007 Jan 26.

7.

Valproic Acid: second generation.

Bialer M, Yagen B.

Neurotherapeutics. 2007 Jan;4(1):130-7. Review.

PMID:
17199028
8.

Histone deacetylase inhibitors reverse gene silencing in Friedreich's ataxia.

Herman D, Jenssen K, Burnett R, Soragni E, Perlman SL, Gottesfeld JM.

Nat Chem Biol. 2006 Oct;2(10):551-8. Epub 2006 Aug 20. Erratum in: Nat Chem Biol. 2007 Jul;3(7):432.

PMID:
16921367
9.

Antitumor activity of a small-molecule inhibitor of human silent information regulator 2 enzymes.

Heltweg B, Gatbonton T, Schuler AD, Posakony J, Li H, Goehle S, Kollipara R, Depinho RA, Gu Y, Simon JA, Bedalov A.

Cancer Res. 2006 Apr 15;66(8):4368-77.

10.

Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation.

Pruitt K, Zinn RL, Ohm JE, McGarvey KM, Kang SH, Watkins DN, Herman JG, Baylin SB.

PLoS Genet. 2006 Mar;2(3):e40. Epub 2006 Mar 31.

11.

Cancer-specific functions of SIRT1 enable human epithelial cancer cell growth and survival.

Ford J, Jiang M, Milner J.

Cancer Res. 2005 Nov 15;65(22):10457-63.

12.

Mammalian SIRT1 limits replicative life span in response to chronic genotoxic stress.

Chua KF, Mostoslavsky R, Lombard DB, Pang WW, Saito S, Franco S, Kaushal D, Cheng HL, Fischer MR, Stokes N, Murphy MM, Appella E, Alt FW.

Cell Metab. 2005 Jul;2(1):67-76. Erratum in: Cell Metab. 2006 Jan;3(1):75.

13.

hMOF histone acetyltransferase is required for histone H4 lysine 16 acetylation in mammalian cells.

Taipale M, Rea S, Richter K, Vilar A, Lichter P, Imhof A, Akhtar A.

Mol Cell Biol. 2005 Aug;25(15):6798-810.

14.

Differential epigenetic modifications in the FMR1 gene of the fragile X syndrome after reactivating pharmacological treatments.

Tabolacci E, Pietrobono R, Moscato U, Oostra BA, Chiurazzi P, Neri G.

Eur J Hum Genet. 2005 May;13(5):641-8.

15.

SIRT1 functionally interacts with the metabolic regulator and transcriptional coactivator PGC-1{alpha}.

Nemoto S, Fergusson MM, Finkel T.

J Biol Chem. 2005 Apr 22;280(16):16456-60. Epub 2005 Feb 16.

16.

Molecular dissection of the events leading to inactivation of the FMR1 gene.

Pietrobono R, Tabolacci E, Zalfa F, Zito I, Terracciano A, Moscato U, Bagni C, Oostra B, Chiurazzi P, Neri G.

Hum Mol Genet. 2005 Jan 15;14(2):267-77. Epub 2004 Nov 24.

PMID:
15563507
17.

Histone deacetylase inhibition by sodium butyrate chemotherapy ameliorates the neurodegenerative phenotype in Huntington's disease mice.

Ferrante RJ, Kubilus JK, Lee J, Ryu H, Beesen A, Zucker B, Smith K, Kowall NW, Ratan RR, Luthi-Carter R, Hersch SM.

J Neurosci. 2003 Oct 15;23(28):9418-27.

18.

Expression of the FMR1 gene.

Tassone F, Hagerman PJ.

Cytogenet Genome Res. 2003;100(1-4):124-8. Review.

PMID:
14526172
19.
20.

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, ameliorates motor deficits in a mouse model of Huntington's disease.

Hockly E, Richon VM, Woodman B, Smith DL, Zhou X, Rosa E, Sathasivam K, Ghazi-Noori S, Mahal A, Lowden PA, Steffan JS, Marsh JL, Thompson LM, Lewis CM, Marks PA, Bates GP.

Proc Natl Acad Sci U S A. 2003 Feb 18;100(4):2041-6. Epub 2003 Feb 7.

Supplemental Content

Support Center